Hyatt Hotels — Nov 6, 2025 release
Fiscal 2025 third-quarter results · 8-K Item 2.02 · Exhibit 99.1 · 0001468174-25-000108
Showing in the filing
Net rooms growth excluding acquisitions
“6.3% to 7.0%”
Period
FY2025
Measure
Company-defined measure
Source
Prose
All guidance in this release · 31
Net rooms growth excluding acquisitions for FY2025
“6.3% to 7.0%”
Net income for FY2025
“$70 million and $86 million”
Adjusted EBITDA for FY2025
“$1,090 million and $1,110 million”
Adjusted EBITDA increase (adjusted for asset… for FY2025
“7% to 9%”
Adjusted EBITDA impact related to economics … for FY2025
“expected to more than double from 2025 to 2027 with anticipated continued growth in future years”
Cash dividend for Q4 FY2025
“$0.15 per share”
Cash dividend declared per share for Q4 FY2025
“$0.15 per share”
System-Wide Hotels RevPAR Growth - Hyatt (Ex… for FY2025
“2% to 2.5%”
Net Rooms Growth - Hyatt (Ex-Playa) for FY2025
“6.3% to 7%”
Net income attributable to Hyatt Hotels Corp… for FY2025
“$70 - $86”
Gross Fees - Hyatt (Ex-Playa) for FY2025
“$1,195 - $1,205”
Adjusted G&A Expenses - Hyatt (Ex-Playa) for FY2025
“$440 - $445”
Adjusted EBITDA - Hyatt (Ex-Playa) for FY2025
“$1,090 - $1,110”
Capital Expenditures - Hyatt (Ex-Playa) for FY2025
“Approx. $150”
Adjusted Free Cash Flow - Hyatt (Ex-Playa) for FY2025
“$475 - $525”
Capital Returns to Shareholders - Hyatt (Ex-… for FY2025
“Approx. $350”
System-wide RevPAR outlook (implied quarterl… for Q4 FY2025
“0.5% at the low end of our range and 2.5% at the high end of our range”
Net Rooms Growth - Playa for FY2025
“0.7%”
Net Rooms Growth - Consolidated for FY2025
“7% to 7.7%”
Net income attributable to Hyatt Hotels Corp… for FY2025
“$(124) - $(121)”
Net income attributable to Hyatt Hotels Corp… for FY2025
“$(54) - $(35)”
Gross Fees - Playa for FY2025
“Approx. $(5)”
Gross Fees - Consolidated for FY2025
“$1,190 - $1,200”
Adjusted G&A Expenses - Playa for FY2025
“$6 - $7”
Adjusted G&A Expenses - Consolidated for FY2025
“$446 - $452”
Adjusted EBITDA - Playa for FY2025
“$70 - $85”
Adjusted EBITDA - Consolidated for FY2025
“$1,160 - $1,195”
Capital Expenditures - Playa for FY2025
“$75”
Capital Expenditures - Consolidated for FY2025
“Approx. $225”
Adjusted Free Cash Flow - Playa for FY2025
“$(25)”
Adjusted Free Cash Flow - Consolidated for FY2025
“$450 - $500”
Exhibit 99.1 · the passage around this item
… earlier in the release
Refer to page 3 and the tables beginning on schedule A-11 for the impact of the Playa Hotels Acquisition on the full year outlook, which has been adjusted to reflect the potential impact from Hurricane Melissa. ◦ Comparable system-wide hotels RevPAR growth is projected between 2% to 2.5%, compared to the full year 2024 ◦ Net rooms growth excluding acquisitions is projected between 6.3% to 7.0%, compared to the full year 2024 ◦ Net income is projected between $70 million and $86 million ◦ Adjusted EBITDA is projected between $1,090 million and $1,110 million, an increase of 7% to 9% after adjusting for assets sold in 2024, compared to the full year 2024 ◦ Capital returns to shareholders is projected to be approximately $350 million, through a combination of dividends and share repurchases Subsequent to the end of the third quarter, the Company announced an expanded agreement with Chase that rewards World of Hyatt cardmembers for stays across Hyatt's global portfolio. The impact to Adjusted EBITDA related to the economics of the credit card programs and similar third-party relationships is expected to more than double from 2025 to 2027 with anticipated continued growth in future years. Mark S. Hoplamazian, President and Chief Executive Officer of Hyatt, said, “Our third quarter results reflect the strength of our core fee business and our disciplined approach to cost management. As we continue our evolution to a brand-led organization, we are focused on elevating guest experiences, deepening customer loyalty through World of Hyatt, and expanding into high-growth segments
later in the release …
the item shown at left
other guidance in this release
Text is the filed exhibit, verbatim.